Bullish
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia
Bausch Health, Canada Inc. has reached a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for public drug plan coverage of ...